Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Voices of TB

Videos from the Global Health Community

Featured Videos

Kenya Launches Child-Friendly TB Medicine

New Childhood TB Medicines Will Help Save Lives

Dr. Eristavi's Story of #TBCourage

John Rovie's Story of #TBCourage

Dr. Gamkrelidze's Story of #TBCourage

Bongiswa's Story of #TBCourage

Nikoloz and Davit's Stories of #TBCourage

Dr. Janice Caoili's Story of #TBCourage

A Conversation with Mitchell Warren

TB & HIV: A Dual Epidemic

Jerick's Story of #TBCourage

Karl Hofmann: Better medicines for children with TB

Outcomes from UN High-Level Meeting on TB

TB Alliance in 2017

  • Show more videos

Filter by Subject

Community Engagement (15)
CPTR (5)
Drug-resistance (23)
Market Access (6)
Patient Stories (21)
Pediatric TB (21)
Resource Mobilization (8)
TB-HIV (4)
TB Research (22)
TB Awareness (27)
TB Alliance (24)
TB Advocacy (23)
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2021 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern